BioCentury
ARTICLE | Clinical News

CXA-201: Phase III started

October 24, 2011 7:00 AM UTC

Cubist began a double-blind, double-dummy, international Phase III trial to compare 1,500 mg IV CXA-201 every 8 hours in combination with 500 mg IV metronidazole every 8 hours for 4-14 days vs. 1,000 ...